상세 보기

Randomized phase III ANGEL study of rivoceranib (apatinib) plus best supportive care (BSC) vs placebo plus BSC in patients with advanced/metastatic gastric cancer who failed >= 2 prior chemotherapy regimens

Kang, Y-K.;
Kang, W. K.;
Di Bartolomeo, M.;
Chau, I.;
Yoon, H. H.;
... Oh, S. C.;
외 14명

제목: Randomized phase III ANGEL study of rivoceranib (apatinib) plus best supportive care (BSC) vs placebo plus BSC in patients with advanced/metastatic gastric cancer who failed >= 2 prior chemotherapy regimens

저자: Kang, Y-K.; Kang, W. K.; Di Bartolomeo, M.; Chau, I.; Yoon, H. H.; Cascinu, S.; Ryu, M-H.; Kim, J. G.; Lee, K-W.; Oh, S. C.; Takashima, A.; Kryzhanivska, A.; Chao, Y.; Vladimirov, V.; Evesque, L.; Schenker, M.; McGinn, A.; Sankar, N.; Wyrwicz, L.; Boku, N.

DOI: 10.1093/annonc/mdz394.034

발행일: 2019-10

학회명: 44th Congress of the European-Society-for-Medical-Oncology (ESMO)

개최지: Barcelona, SPAIN

개최국가: 영국

학회 개최일: 2019-09-27 ~ 2019-10-01

언어: ENG